Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies
Open Access
- 7 October 2026
- journal article
- other
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 173
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (R00CA277136)
This publication has 15 references indexed in Scilit:
- Genomic features do not account for differences in multiple myeloma risk by ancestryBlood Cancer Discovery, 2026
- Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023eJHaem, 2026
- Equal survival for Black Americans with multiple myeloma when appropriately matched to White AmericansBlood Cancer Journal, 2025
- Racial disparities in multiple myelomaBlood Global Hematology, 2025
- Disparities in time to treatment with oral antimyeloma medicationsBlood Cancer Journal, 2024
- A roadmap towards improving outcomes in multiple myelomaBlood Cancer Journal, 2024
- Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial DisparitiesClinical Lymphoma Myeloma and Leukemia, 2023
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic ReviewClinical Lymphoma Myeloma and Leukemia, 2023
- Overlap WeightingJAMA, 2020
- Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood AtlasNew England Journal of Medicine, 2018